Excretion of hepatitis a virus antigen in feces in acute and prolonged hepatitis a infection
Dautović-Krkić, S.; Cećuk, D.
Medicinski Arhiv 58(1): 15-18
2004
ISSN/ISBN: 0025-8083 PMID: 15017897 Document Number: 572945
The excretion of the antigen hepatitis A virusa (Ag HAV) in stool in the acute phase develops in the course of the incubation and the early symptomatic illness phase, what amounts maximally to 60 days. In the available literature there are no data regarding to the length of the excretion of Ag HAV in the stored forms of the illness (PTHA). Of this paper was to examine the relation of the excretion length Ag-HAV in stool according to the maintenance length of the pathologic activities the alaninaminotranspherase (ALT), the persistence of the antibodies to Ag-HAV IgM class (anti-HAV IgM) and the maintenance of the increased values of the circulating immune complex (CiC) in the serum of the ill become with PTHA. In the three year prospective study of the values of the circulating immune complex in stool of 10 suffering from acute hepatitis A, and 39 ill become with the protrahirated form of HAV-infection. Ag-HAV in stool is determined by the method the flow through immunoelectroosmophores (IOEP). IgM anti-HAV was determined by ELISA method. CiC have determined photometrically in the sediment polictilenglycole. Of the researches show that FALI Ag HAV u obje grupe pacijenata izlucuje prvo permanentno, potom intermitentno. In the group with acute HAV infection svi pacijenti su imali pozitivan nalaz Ag-HAV in stool. In PTH group in 61% examina was found Ag-HAV, and in 39% was not found either stool sample. The longest excretion of Ag-HAV in stool was verified during the third recrudescence, 5.5 month from the beginning of HAV-infection, that is on the 159-th day of the illness. The results of the researches has shown that the excreation of Ag-HAV in stool approximately equally to the maintenance of the increased values ALT, and three fold shorter than the maintenance of IgM anti-HAV and the patologic values CiC in patient serum with PTHA.